Roxana Edith Heriseanu1, Priyadarshini Chari2. 1. Spinal Injuries Unit, Royal Rehab, Ryde, NSW, Australia. roxana.heriseanu@royalrehab.com.au. 2. Spinal Injuries Unit, Royal North Shore Hospital, St Leonards, NSW, Australia. Priyadarshini.chari@health.nsw.gov.au.
Abstract
INTRODUCTION: Myositis of unknown aetiology might be a very rare complication of intramuscular injections of onabotulinum toxin A (Botox) for spasticity treatment. CASE PRESENTATION: We describe a case of significant myositis of unknown aetiology in a 17-year-old man, who was admitted for rehabilitation 4 months after his initial spinal cord injury (SCI) as a result of a mountain bike accident. He has an incomplete tetraplegia, C4 AIS B international Standards for Neurological Classification for Spinal Cord Injury (ISNCSCI) [1] due to C5 vertebra 3 column fracture [2]. He had severe spasticity of his lower limb muscles treated with Botox, following which, he required two acute hospital transfers for diagnosis and management of myositis. DISCUSSION: This is a severe unusual presentation of myositis caused by intramuscular botulinum toxin for treatment of spasticity, in the frequent setting of spasticity where intramuscular botulinum toxin injections are routinely used.
INTRODUCTION: Myositis of unknown aetiology might be a very rare complication of intramuscular injections of onabotulinum toxin A (Botox) for spasticity treatment. CASE PRESENTATION: We describe a case of significant myositis of unknown aetiology in a 17-year-old man, who was admitted for rehabilitation 4 months after his initial spinal cord injury (SCI) as a result of a mountain bike accident. He has an incomplete tetraplegia, C4 AIS B international Standards for Neurological Classification for Spinal Cord Injury (ISNCSCI) [1] due to C5 vertebra 3 column fracture [2]. He had severe spasticity of his lower limb muscles treated with Botox, following which, he required two acute hospital transfers for diagnosis and management of myositis. DISCUSSION: This is a severe unusual presentation of myositis caused by intramuscular botulinum toxin for treatment of spasticity, in the frequent setting of spasticity where intramuscular botulinum toxin injections are routinely used.
Authors: Koenraad De Boulle; William Philip Werschler; Michael H Gold; Suzanne Bruce; Gerhard Sattler; Patricia Ogilvie; James Street; Kristin E Larsen; Irina Yushmanova; Xiaofang Lei; Elisabeth Lee; Domenico Vitarella; Cheri Mao Journal: Dermatol Surg Date: 2018-11 Impact factor: 3.398
Authors: Theodore Wein; Alberto Esquenazi; Wolfgang H Jost; Anthony B Ward; Grace Pan; Rozalina Dimitrova Journal: PM R Date: 2018-01-09 Impact factor: 2.298
Authors: Carlo Trompetto; Lucio Marinelli; Laura Mori; Elisa Pelosin; Antonio Currà; Luigi Molfetta; Giovanni Abbruzzese Journal: Biomed Res Int Date: 2014-10-30 Impact factor: 3.411